Downregulation of miR26A1 has been reported in various B-cell malignancies; however, the mechanism behind its deregulation remains largely unknown. We investigated miR26A1 methylation and expression levels in a well-characterized series of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). From 450K methylation arrays, we first observed miR26A1 (cg26054057) as uniformly hypermethylated in MCL (n = 24) (all >75%), while CLL (n = 18) showed differential methylation between prognostic subgroups. Extended analysis using pyrosequencing confirmed our findings and real-time quantitative PCR verified low miR26A1 expression in both CLL (n = 70) and MCL (n = 38) compared to normal B-cells. Notably, the level of miR26A1 methylation predicted outcome in CLL, with higher levels seen in poor-prognostic, IGHV-unmutated CLL. Since EZH2 was recently reported as a target for miR26A1, we analyzed the expression levels of both miR26A1 and EZH2 in primary CLL samples and observed an inverse correlation. By overexpression of miR26A1 in CLL and MCL cell lines, reduced EZH2 protein levels were observed using both Western blot and flow cytometry. In contrast, methyl-inhibitor treatment led to upregulated miR26A1 expression with a parallel decrease of EZH2 expression. Finally, increased levels of apoptosis were observed in miR26A1-overexpressing cell lines, further underscoring the functional relevance of miR26A1. In summary, we propose that epigenetic silencing of miR26A1 is required for the maintenance of increased levels of EZH2, which in turn translate into a worse outcome, as shown in CLL, highlighting miR26A1 as a tumor suppressor miRNA.

b Department of Immunology Genetics and Pathology Science for Life Laboratory Uppsala University Uppsala Sweden

c Central European Institute of Technology Masaryk University and University Hospital Brno Czech Republic

Department of Clinical Chemistry and Transfusion Medicine Institute of Biomedicine Sahlgrenska Academy Gothenburg University Sweden

Department of Laboratory Medicine Division of Pathology Karolinska University Hospital Sweden

e Department of Molecular Medicine University of Pavia Italy

See more in PubMed

Tashkandi H, Shah N, Patel Y, Chen H. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience 2015; 2:924-9; PMID:26697527 PubMed PMC

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002 PubMed DOI PMC

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al.. MicroRNA gene expression deregulation in human breast cancer. Cancer research 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783 PubMed DOI

Omrane I, Kourda N, Stambouli N, Privat M, Medimegh I, Arfaoui A, Uhrhammer N, Bougatef K, Baroudi O, Bouzaienne H, et al.. MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization. Biomed Res Int 2014; 2014:584852; PMID:24800242; http://dx.doi.org/10.1155/2014/584852 PubMed DOI PMC

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al.. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799 PubMed DOI PMC

Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al.. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004; 101:11755-60; PMID:15284443; http://dx.doi.org/10.1073/pnas.0404432101 PubMed DOI PMC

Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al.. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353:1793-801; PMID:16251535; http://dx.doi.org/10.1056/NEJMoa050995 PubMed DOI

Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, et al.. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109:4944-51; PMID:17327404; http://dx.doi.org/10.1182/blood-2006-12-062398 PubMed DOI

Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, Lugar PL, Lagoo AS, Rizzieri DA, Friedman DR, et al.. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113:4586-94; PMID:19202128; http://dx.doi.org/10.1182/blood-2008-09-178186 PubMed DOI PMC

Deng SY, Guo XX, Wang N, Wang KH, Wang S. Network analysis of microRNAs, genes and their regulation in mantle cell lymphoma. Asian Pac J Cancer Prev 2015; 16:457-63; PMID:25684471; http://dx.doi.org/10.7314/APJCP.2015.16.2.457 PubMed DOI

Husby S, Geisler C, Gronbaek K. MicroRNAs in mantle cell lymphoma. Leuk Lymphoma 2013; 54:1867-75; PMID:23339447; http://dx.doi.org/10.3109/10428194.2013.766731 PubMed DOI

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, et al.. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007; 26:7590-5; PMID:17563749; http://dx.doi.org/10.1038/sj.onc.1210564 PubMed DOI

Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112:4202-12; PMID:18713946; http://dx.doi.org/10.1182/blood-2008-03-147645 PubMed DOI

Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8:172-5; PMID:19106613; http://dx.doi.org/10.4161/cc.8.1.7292 PubMed DOI

Luzi E, Marini F, Sala SC, Tognarini I, Galli G, Brandi ML. Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res 2008; 23:287-95; PMID:18197755; http://dx.doi.org/10.1359/jbmr.071011 PubMed DOI

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al.. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075 PubMed DOI

Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al.. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100:11606-11; PMID:14500907; http://dx.doi.org/10.1073/pnas.1933744100 PubMed DOI PMC

Heyn H, Esteller M. EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis. Cancer Cell 2013; 23:563-5; PMID:23680141; http://dx.doi.org/10.1016/j.ccr.2013.04.028 PubMed DOI

Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, et al.. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850 PubMed DOI

Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205:113-23; PMID:22469510; http://dx.doi.org/10.1016/j.cancergen.2012.01.002 PubMed DOI

Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Rezania D, Dalton WS, et al.. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115:2630-9; PMID:20086245; http://dx.doi.org/10.1182/blood-2009-09-243147 PubMed DOI PMC

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, et al.. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22:506-23; PMID:23079660; http://dx.doi.org/10.1016/j.ccr.2012.09.003 PubMed DOI PMC

Cahill N, Bergh AC, Kanduri M, Goransson-Kultima H, Mansouri L, Isaksson A, Ryan F, Smedby KE, Juliusson G, Sundstrom C, et al.. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2013; 27:150-8; PMID:22922567; http://dx.doi.org/1047771210.1038/leu.2012.245 PubMed DOI

Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, et al.. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7; PMID:10477712 PubMed

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54; PMID:10477713 PubMed

Yu L, Lu J, Zhang B, Liu X, Wang L, Li SY, Peng XH, Xu X, Tian WD, Li XP. miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2. Oncol Lett 2013; 5:1223-8; PMID:23599767; http://dx.doi.org/10.3892/ol.2013.1173 PubMed PMC

Wang G, Sun Y, He Y, Ji C, Hu B, Sun Y. miR-26a promoted by interferon-α inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2. Genet Test Mol Biomarkers 2015; 19:30-6; PMID:25494962; http://dx.doi.org/10.1089/gtmb.2014.0245 PubMed DOI

Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, Isaksson A, Rosenquist R. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010; 115:296-305; PMID:19897574; http://dx.doi.org/10.1182/blood-2009-07-232868 PubMed DOI

Kanduri M, Marincevic M, Halldorsdottir AM, Mansouri L, Junevik K, Ntoufa S, Kultima HG, Isaksson A, Juliusson G, Andersson PO, et al.. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 2012; 7:1435-42; PMID:23154584; http://dx.doi.org/10.4161/epi.22901 PubMed DOI PMC

Halldorsdottir AM, Kanduri M, Marincevic M, Mansouri L, Isaksson A, Goransson H, Axelsson T, Agarwal P, Jernberg-Wiklund H, Stamatopoulos K, et al.. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. Am J Hematol 2012; 87:361-7; PMID:22374828; http://dx.doi.org/10.1002/ajh.23115 PubMed DOI

Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, et al.. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44:1236-42; PMID:23064414; http://dx.doi.org/10.1038/ng.2443 PubMed DOI

Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, et al.. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 2016; PMID:26780610; http://dx.doi.org/10.1038/ng.3488 PubMed PMC

Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22:5323-35; PMID:14532106; http://dx.doi.org/10.1093/emboj/cdg542 PubMed DOI PMC

Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, et al.. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67:10657-63; PMID:18006806; http://dx.doi.org/10.1158/0008-5472.CAN-07-2498 PubMed DOI

Kanduri M, Sander B, Ntoufa S, Papakonstantinou N, Sutton LA, Stamatopoulos K, Kanduri C, Rosenquist R. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Epigenetics 2013; 8:1280-8; PMID:24107828; http://dx.doi.org/10.4161/epi.26546 PubMed DOI PMC

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56; PMID:18216293; http://dx.doi.org/10.1182/blood-2007-06-093906 PubMed DOI PMC

Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117:5019-32; PMID:21300984; http://dx.doi.org/10.1182/blood-2011-01-293050 PubMed DOI PMC

Martinelli S, Kanduri M, Maffei R, Fiorcari S, Bulgarelli J, Marasca R, Rosenquist R. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics 2013; 8:720-9; PMID:23803577; http://dx.doi.org/10.4161/epi.24947 PubMed DOI PMC

Rosen A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, Rasul A, Bjorkholm M, Jansson M, Mansouri L, et al.. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology 2012; 1:18-27; PMID:22720208; http://dx.doi.org/10.4161/onci.1.1.18400 PubMed DOI PMC

Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K, et al.. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Res 1999; 23:127-36; PMID:10071128; http://dx.doi.org/10.1016/S0145-2126(98)00154-4 PubMed DOI

Estrov Z, Talpaz M, Ku S, Harris D, Van Q, Beran M, Hirsch-Ginsberg C, Huh Y, Yee G, Kurzrock R. Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia. Leukemia Res 1998; 22:341-53; PMID:9669839; http://dx.doi.org/10.1016/S0145-2126(97)00191-4 PubMed DOI

Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, et al.. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997; 11:64-72; http://dx.doi.org/10.1038/sj.leu.2400555 PubMed DOI